Skip to main content
LUCENT-1: Mirikizumab sees phase 3 success in UC treatment
Primary tabs
•••
View
Get Stamp Tags
Published Locations
Breadcrumb
Home
LUCENT-1: Mirikizumab sees phase 3 success in UC treatment
User login
Username
Password
Reset your password
Concept
Lead
score
Ulcerative Colitis
1
1
Biologic Therapy
0
0.99
Inflammatory Bowel Disease
0
0.74
Remission
0
0.59
Colitis
0
0.47
Corticosteroids
0
0.36
Interleukin
0
0.98
Humanized Monoclonal Antibody
0
0.17
Adverse Effects
0
0.12
Board Certification
0
0.12
Endoscopy
0
0.12
Europe
0
0.12
Fatigue
0
0.12
Hemorrhage
0
0.12
Histology
0
0.12
Immunomodulator
0
0.12
Monoclonal Antibody
0
0.12
Rectal Hemorrhage
0
0.12
Steroids
0
0.12
Crohn Disease
0
0.11
Patient Safety
0
0.11
Psoriasis
0
0.11
Specialty
Lead
score
Internal Medicine
1
1
Gastroenterology
0
0.9